Why I’ve just bought GSK shares for my Stocks and Shares ISA

GSK shares have looked tempting to me since they demerged their consumer healthcare business this month, and here’s why I rate them a buy.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A senior woman sits up on the exam table at a doctors appointment. She is dressed casually in a blue sweater and has a smile on her face as she glances at the doctor. Her female doctor is wearing a white lab coat and seated in front of her as she takes notes on a tablet.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GSK (LSE:GSK) shares have held up well in this year’s market turmoil. Furthermore, on 18 July the company demerged its consumer healthcare business so is now purely a pharmaceutical company.

This is important news for investors like me. It changes the way the company is viewed by potential stock market predators in the pharmaceutical sector, and I am always on the lookout for the next likely takeover candidate. Additionally, any capital gain within my Stocks and Shares ISA is tax-free.

Takeover appeal

Before the demerger, GSK was a large mouthful for a possible predator such as Pfizer to swallow. But now GSK is a bitesize treat, with a stock market valuation of just £71bn compared to Pfizer’s £240bn and the even bigger Johnson & Johnson’s £377bn. If the British pound continues to weaken against the US dollar then a takeover would become even more appealing for a buyer.

For a takeover to succeed, the purchase price would likely be far in excess of GSK’s current valuation. Additionally, takeovers and profitable mergers have clearly had a long history in the pharmaceutical industry, e.g. AstraZeneca (Astra and Zeneca), and Glaxo and SmithKline. These giants often grow this way. It may or may not happen, of course, but I feel there is more upside potential than downside to purchasing the shares.

Long-term positives

If a takeover doesn’t transpire then I think the future should still be quite bright for GSK. It hasn’t got much debt as it parcelled this off when demerging the consumer healthcare company (which is now named Haleon). Debt is a hindrance to a company, especially in a time of rising interest rates around the world, but GSK has the capacity to invest heavily in research and development for ongoing success.  

GSK is very nicely placed in the field of vaccines, catering for a growing global population. After two years of a Covid-19 pandemic, most world leaders have grasped the importance of having a vaccine that works, and of holding plentiful supplies of it.

GSK’s pharma business is also strong. The company anticipates underlying operating profits to grow at circa 10% per annum.

We’re in a cost-of-living crisis with high inflation across the globe. Some companies will flounder in this environment, since if they raise their products’ prices, their customers may not be able to afford them or just choose not to buy them. But medicines and vaccines are almost an essential purchase, and GSK will likely be able to raise its prices in line with inflation and remain profitable.

Also, in a time of volatility caused by war, pharma is a good defensive sector of the stock market to be invested in.

GSK shares’ negatives

Post demerger, the company’s dividend will be lower than in previous years, so if income had been a priority for me, then there are better options than GSK.

New drugs could fail during trials, and existing patent protections on GSK’s products will eventually expire, which means GSK’s competitors can launch generic versions of its best-selling drugs. So the company has to keep discovering new drugs and manufacturing successful vaccines to prosper.

On balance, however, I am a fan of GSK and have invested in it for the long term.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Michael Wood-Wilson owns GSK shares. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Surely, the Rolls-Royce share price can’t go any higher in 2025?

The Rolls-Royce share price was the best performer on the FTSE 100 in 2023 and so far in 2024. Dr…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

Here’s how an investor could start buying shares with £100 in January

Our writer explains some of the things he thinks investors on a limited budget should consider before they start buying…

Read more »

Investing Articles

Forget FTSE 100 airlines! I think shares in this company offer better value to consider

Stephen Wright thinks value investors looking for shares to buy should include aircraft leasing company Aercap. But is now the…

Read more »

Investing Articles

Are Rolls-Royce shares undervalued heading into 2025?

As the new year approaches, Rolls-Royce shares are the top holding of a US fund recommended by Warren Buffett. But…

Read more »

Investing Articles

£20k in a high-interest savings account? It could be earning more passive income in stocks

Millions of us want a passive income, but a high-interest savings account might not be the best way to do…

Read more »

Investing Articles

3 tried and tested ways to earn passive income in 2025

Our writer examines the latest market trends and economic forecasts to uncover three great ways to earn passive income in…

Read more »

Investing Articles

Here’s what £10k invested in the FTSE 100 at the start of 2024 would be worth today

Last week's dip gives the wrong impression of the FTSE 100, which has had a pretty solid year once dividends…

Read more »

Investing Articles

UK REITs: a once-in-a-decade passive income opportunity?

As dividend yields hit 10-year highs, Stephen Wright thinks real estate investment trusts could be a great place to consider…

Read more »